Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 10:55 a.m. E.T.

A live webcast of the presentation will be accessible in the Investor Relations section of the Aimmune website at www.aimmune.com. A replay will be available following the webcast.

About Aimmune

Aimmune Therapeutics, Inc. is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies. For more information, please visit www.aimmune.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200807005046/en/

Investors: DeDe Sheel (917) 834-1494 dsheel@aimmune.com

Media: Jodi Sievers (628) 250-6849 Jsievers@aimmune.com

Aimmune Therapeutics (NASDAQ:AIMT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024